Breast最新文献

{"title":"Perceived financial toxicity after active treatment and its association with clinical outcomes among breast cancer survivors: A prospective cohort study","authors":"Doyoun Woen ,&nbsp;Danbee Kang ,&nbsp;Juwon Park ,&nbsp;Hyunsoo Kim ,&nbsp;Su Min Lee ,&nbsp;Seok Jin Nam ,&nbsp;Seok Won Kim ,&nbsp;Jeong Eon Lee ,&nbsp;Jong Han Yu ,&nbsp;Byung Joo Chae ,&nbsp;Jai Min Ryu ,&nbsp;Woong Ki Park ,&nbsp;Juhee Cho ,&nbsp;Se Kyung Lee","doi":"10.1016/j.breast.2026.104697","DOIUrl":"10.1016/j.breast.2026.104697","url":null,"abstract":"<div><h3>Background</h3><div>Perceived financial toxicity (FT) is an increasingly recognized concern among cancer survivors. However, its association with long-term oncologic outcomes, particularly after completion of active treatment, remains underexplored.</div></div><div><h3>Methods</h3><div>We conducted a prospective cohort study of 4163 breast cancer survivors from a tertiary cancer center in South Korea. Eligible participants were within 18 months of diagnosis, had completed surgery and any adjuvant chemotherapy or radiotherapy, and had no evidence of recurrence at enrollment. Perceived FT was assessed using the Comprehensive Score for Financial Toxicity (COST) questionnaire. FT was defined by a COST score &lt;26. Primary outcome was recurrence-free survival (RFS), and secondary outcomes included all-cause mortality and quality-of-life (QoL) domains. Multivariable Cox proportional hazard models adjusted for age, stage, treatment, and socioeconomic factors.</div></div><div><h3>Results</h3><div>Among the cohort, 2109 (50.7 %) patients reported perceived FT after active treatment. FT was independently associated with increased risk of recurrence or death (HR 1.42, 95 % CI 1.08–1.87), and higher all-cause mortality (HR 1.74, 95 % CI 1.02–2.97). FT was also associated with significantly worse emotional functioning, social functioning, and future outlook.</div></div><div><h3>Conclusions</h3><div>Perceived financial toxicity following active breast cancer treatment was associated with worse oncologic and quality-of-life outcomes, regardless of objective socioeconomic status. These findings underscore the need for routine assessment of perceived financial burden during survivorship care and targeted financial interventions, even in patients without traditionally defined financial vulnerability.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"85 ","pages":"Article 104697"},"PeriodicalIF":7.9,"publicationDate":"2026-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146017352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Short commentaries on data published by Yono et al. on avoiding breast cancer–related arm lymphedema with the lymphatic microsurgical preventive healing approach","authors":"Da Qian ,&nbsp;Xuli Meng ,&nbsp;Min Jia","doi":"10.1016/j.breast.2025.104689","DOIUrl":"10.1016/j.breast.2025.104689","url":null,"abstract":"<div><div>Lymphatic microsurgical preventive healing approach (LyMPHA) is being adopted to prevent arm lymphedema after axillary lymph node dissection (ALND), but open questions remain over selection bias, non-standardized endpoints and variable surgical protocols before robust evidence is available.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"85 ","pages":"Article 104689"},"PeriodicalIF":7.9,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145951510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The efficacy of intra-operative injection of [99mTc] labelled colloidal nanoparticles for sentinel lymph nodes identification in breast cancer","authors":"Or Barkai ,&nbsp;Itamar Ashkenazi ,&nbsp;Aviad Hoffman","doi":"10.1016/j.breast.2026.104695","DOIUrl":"10.1016/j.breast.2026.104695","url":null,"abstract":"<div><h3>Background</h3><div>Sentinel lymph node (SLN) biopsy is a critical component of axillary staging in breast cancer management. Traditionally, Technetium-99m (Tc-99m) labelled colloidal nanoparticles is injected preoperatively in the nuclear medicine suite, followed by imaging, while blue dye is injected intraoperatively. Despite the use of topical anesthetics, preoperative radio-tracer injections can be painful, time-intensive, and resource-demanding. To address these limitations, we implemented intraoperative radio-tracer injection under anesthesia, instead of the traditional procedure at the nuclear imaging suite. This study evaluates whether intraoperative Tc-99m labelled colloidal nanoparticles administration affects SLN identification rates.</div></div><div><h3>Materials and methods</h3><div>A retrospective analysis of breast cancer patients who underwent surgery at Rambam Health Care Campus (2020–2023). Unfiltered Tc-99m sulphur colloid and blue dye were injected intraoperatively, and SLN detection rates were assessed.</div></div><div><h3>Results</h3><div>Among 350 patients (352 procedures), radioactive SLNs were successfully identified using Tc-99m in 89.5 % of cases. When both Tc-99m labelled colloidal nanoparticles and blue dye were used, the identification rate increased to 93.2 %. SLN detection was higher in upfront surgery compared to neoadjuvant therapy cases (radio-tracer alone: 92.2 % vs. 85.1 %, p = 0.048; dual tracer: 95.9 % vs. 88.8 %, p = 0.015). Advanced T-stage (OR 5.1, 95 %CI 2.3, 11.3; p &lt; 0.001) and N-stage (OR 3.7, 95 %CI 1.8, 7.3; p &lt; 0.001) were associated with lower SLN detection rates.</div></div><div><h3>Conclusions</h3><div>Intraoperative Tc-99m labelled colloidal nanoparticles injection is an effective alternative to preoperative injection, achieving comparable SLN detection rates while eliminating patient discomfort, reducing procedural complexity, and optimizing surgical workflow.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"85 ","pages":"Article 104695"},"PeriodicalIF":7.9,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145973273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breast composition and dose deposition to fat and fibroglandular tissues are associated with breast side effects after radiation therapy","authors":"Tanwiwat Jaikuna ,&nbsp;Fiona Wilson ,&nbsp;Carmel Anandadas ,&nbsp;David Azria ,&nbsp;Jenny Chang-Claude ,&nbsp;Maria Carmen De Santis ,&nbsp;Sara Gutiérrez-Enríquez ,&nbsp;Marcel van Herk ,&nbsp;Peter Hoskin ,&nbsp;Lea Kotzki ,&nbsp;Maarten Lambrecht ,&nbsp;Zoe Lingard ,&nbsp;Petra Seibold ,&nbsp;Alejandro Seoane ,&nbsp;Elena Sperk ,&nbsp;R Paul Symonds ,&nbsp;Christopher J. Talbot ,&nbsp;Tiziana Rancati ,&nbsp;Tim Rattay ,&nbsp;Victoria Reyes ,&nbsp;Marianne C. Aznar","doi":"10.1016/j.breast.2026.104694","DOIUrl":"10.1016/j.breast.2026.104694","url":null,"abstract":"<div><h3>Objective</h3><div>Breast comprises different tissues with potentially different dose responses to radiation therapy (RT). This study investigates the correlation between RT dose, breast composition, and side effects from breast RT.</div></div><div><h3>Material/methods</h3><div>Data from 922 early-stage breast cancer patients who underwent breast-conserving surgery and RT from the REQUITE study were included. Breast pain, oedema, atrophy, and induration were assessed immediately post-RT, one-year, and two-years post-RT. Maximum severity scores for each toxicity were used for analysis. Breast tissue was divided into “<em>fat</em>” and “<em>fibroglandular</em>” substructures from computed tomography (CT) using a Gaussian Mixture Model. The correlation between breast characteristics, toxicity, dosimetric parameters, and patient and clinical variables was investigated using ordinal regression. The model's fit was evaluated using the Akaike Information Criterion in SPSS v.29.</div></div><div><h3>Results</h3><div>Breast volume and breast density were associated with increased risk of breast oedema, atrophy, and induration in multivariable analysis (<em>p&lt;</em>0.05). Higher mean dose and dose uniformity were observed for fibroglandular compared to fatty tissue at all severity levels, while there was no significant difference in the maximum dose to either substructure. Higher dose deposit to fat was associated with breast pain and oedema, while breast atrophy and induration were associated with dose to fibroglandular tissue. All best-performing toxicity models included dosimetric parameters derived from breast composition.</div></div><div><h3>Conclusion</h3><div>Breast characterisation offers new insight into the link between dose and toxicity. Breast density and dose parameters from different substructures were associated with different breast toxicity. These findings further support the importance of dose homogeneity of breast RT planning.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"85 ","pages":"Article 104694"},"PeriodicalIF":7.9,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145973277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-effectiveness of inavolisib plus palbociclib-fulvestrant versus palbociclib plus fulvestrant as first-line treatment in HR+/HER2-advanced breast cancer","authors":"Jiaming Zhu ,&nbsp;Ye Ding ,&nbsp;Zhengxiong Li ,&nbsp;Wen Liu","doi":"10.1016/j.breast.2026.104693","DOIUrl":"10.1016/j.breast.2026.104693","url":null,"abstract":"<div><h3>Purpose</h3><div>This study aims to evaluate the cost-effectiveness of inavolisib plus palbociclib-fulvestrant versus palbociclib-fulvestrant for treating advanced HR⁺/HER2^-breast cancer patients with PIK3CA mutations from both United States (U.S.) and Chinese healthcare system perspectives.</div></div><div><h3>Methods</h3><div>A partitioned survival model was used, with survival data from the INAVO120 clinical trials. Primary outcomes assessed were costs, life-years, quality-adjusted life-years (QALYs), and the incremental cost-effectiveness ratio (ICER). Sensitivity analysis was performed to explore the uncertainty of model inputs. Changes in treatment efficacy were modeled to assess their impact on cost-effectiveness. Subgroup analysis was also conducted to refine the findings.</div></div><div><h3>Results</h3><div>In the base-case analysis, the inavolisib triple regimen showed an ICER of $249,487.22/QALY in the U.S. and $43,812.01/QALY in China, both exceeding their respective willingness-to-pay thresholds. Price simulation indicated that the inavolisib-based combination would be preferred in China if the price were reduced to $133.19/9 mg, while a price of $421.13/9 mg would be required to achieve cost-effectiveness in the U.S. Sensitivity analysis demonstrated robust results from the U.S. perspective, while for China, variations in the price of inavolisib and utility of progression-free-survival influenced the conclusions. Subgroup analyses suggested certain patient subgroups could be cost-effective in the Chinese context.</div></div><div><h3>Conclusion</h3><div>Compared with palbociclib-fulvestrant, the inavolisib triple regimen is not cost-effective at its current price. A substantial price reduction or careful selection of the target patient may be required for the regimen to be economically viable.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"85 ","pages":"Article 104693"},"PeriodicalIF":7.9,"publicationDate":"2026-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145910469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness comparison of first-line CDK4/6 inhibitors in patients with hormone-positive HER2-negative advanced breast cancer according to tumor histology: a sub-analysis of the real-world, multicenter, Italian study PALMARES-2","authors":"Giacomo Mazzoli ,&nbsp;Leonardo Provenzano ,&nbsp;Maria Vittoria Dieci ,&nbsp;Giuseppe Curigliano ,&nbsp;Mario Giuliano ,&nbsp;Andrea Botticelli ,&nbsp;Matteo Lambertini ,&nbsp;Gianpiero Rizzo ,&nbsp;Rebecca Pedersini ,&nbsp;Marianna Sirico ,&nbsp;Nicla La Verde ,&nbsp;Alessandra Gennari ,&nbsp;Alberto Zambelli ,&nbsp;Angela Toss ,&nbsp;Marta Piras ,&nbsp;Monica Giordano ,&nbsp;Barbara Tagliaferri ,&nbsp;Daniele Generali ,&nbsp;Donata Sartori ,&nbsp;Giuseppe Fotia ,&nbsp;Claudio Vernieri","doi":"10.1016/j.breast.2026.104692","DOIUrl":"10.1016/j.breast.2026.104692","url":null,"abstract":"<div><h3>Introduction</h3><div>Invasive lobular breast cancer (ILC) is the second most common breast cancer subtype, with distinctive biological and epidemiologic features. Although phase III trials of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in hormone receptor-positive, HER2-negative advanced breast cancer (HR+/HER2-aBC) included patients with ILC, their real-world effectiveness in this population remains poorly characterized.</div></div><div><h3>Material and methods</h3><div>In this sub-analysis of the multicenter, real-world PALMARES-2 study (NCT06805812), we assessed the predictive and prognostic value of lobular histology in HR+/HER2-aBC treated with first-line endocrine therapy (ET) plus CDK4/6i. The primary endpoint was real-world progression-free survival (rwPFS). Associations between histology and outcomes were adjusted for 15 covariates using multivariable Cox-regression and inverse probability of treatment weighting.</div></div><div><h3>Results</h3><div>Among 1982 patients, 367 (18.5 %) had ILC and 1481 (74.7 %) non-special type (NST). Median follow-up was 29.8 and 31.2 months, respectively. ILC was associated with shorter rwPFS versus NST (adjusted hazard ratio [aHR]: 1.24, 95 %CI:1.04–1.47, <em>P=</em>0.017). Palbociclib efficacy was not affected by lobular histology (<em>P</em> for interaction = 0.553) while abemaciclib was less effective in ILC (<em>P</em> = 0.009). All three CDK4/6i achieved similar rwPFS in ILC (ribociclib vs palbociclib: aHR: 1.01, 95 %CI: 0.67–1.45, <em>P</em> = 0.949; abemaciclib vs palbociclib: aHR: 1.13, 95 %CI: 0.75–1.71, <em>P</em> = 0.551; abemaciclib vs ribociclib: aHR: 1.15, 95 %CI: 0.73–1.80, <em>P</em> = 0.549).</div></div><div><h3>Conclusions</h3><div>Tumor histology affects the real-world effectiveness of first line ET plus CDK4/6i. In ILC, all three CDK4/6i performed similarly; therefore, treatment selection should prioritize tolerability, manageability, drug-drug interactions, and patient preferences.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"86 ","pages":"Article 104692"},"PeriodicalIF":7.9,"publicationDate":"2026-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146075841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genomic landscape of metastatic breast cancers in young adults: a liquid biopsy analysis of women aged 20–40 years","authors":"Ernest Diab ,&nbsp;Cyril Roussel-Simonin ,&nbsp;Federica Giugliano ,&nbsp;Julia Dixon-Douglas ,&nbsp;Alessandra Spata ,&nbsp;Martina Pagliuca ,&nbsp;Lauriane Minot ,&nbsp;Alexandre Xu-Vuillard ,&nbsp;Fernanda Mosele ,&nbsp;Thomas Grinda ,&nbsp;Alessandro Viansone ,&nbsp;Chayma Bousrih ,&nbsp;Jean Zeghondy ,&nbsp;Tarek Ben Ahmed ,&nbsp;Claudio Nicotra ,&nbsp;Arnaud Bayle ,&nbsp;Antoine Italiano ,&nbsp;Suzette Delaloge ,&nbsp;Barbara Pistilli ,&nbsp;Fabrice André ,&nbsp;Elie Rassy","doi":"10.1016/j.breast.2025.104690","DOIUrl":"10.1016/j.breast.2025.104690","url":null,"abstract":"<div><h3>Introduction</h3><div>Breast cancer in young adults (YA) aged 20–40 years has distinct clinical and biological traits compared with older patients. This study evaluated the genomic landscape of metastatic breast cancers (MBC) among YA.</div></div><div><h3>Methods</h3><div>Patients with MBC enrolled in the STING molecular profile platform (NCT04932525) between 2021 and May 2023 were included. Clinical and genomic features were analyzed by age (≤40 vs &gt; 40 years). Tumor profiling used the FoundationOne Liquid CDx assay (324 genes) at baseline or later in the disease course. Variant frequencies were compared across age groups.</div></div><div><h3>Results</h3><div>Of 432 eligible patients, 68 (16 %) were YA. Among 37 YA with hormone receptor positive (HR+) BC, frequent alterations included <em>TP53</em> (39 %), <em>ESR1</em> (27 %), <em>PIK3CA</em> (25 %), <em>FGFR3</em> (18 %), <em>FGFR4</em> (18 %), <em>FGFR19</em> (18 %), <em>CCND1</em> (18 %). Compared with older patients, YA with HR + tumors had fewer <em>RB1</em> (7 % vs 8 %; <em>p</em> = 0.03) and <em>PIK3CA</em> (25 % vs 31 %; <em>p</em> = 0.03) alterations. Among 28 YA with triple negative BC, the most common alterations were <em>TP53</em> (100 %), <em>PTEN</em> (26 %), <em>BRCA1</em> (22 %), <em>RB1</em> (17 %). <em>PTEN</em> mutations were more frequent among YA with TNBC than older patients (26 % vs 8 %; <em>p</em> = 0.009). Tiers I-III genomic alterations according to the ESMO scale of clinical actionability (ESCAT) were identified in 54 YA (79 %), including 48 tiers I-II alterations comprising <em>ESR1</em> (n = 12), <em>gBRCA1/2</em> (n = 11), <em>PIK3CA</em> (n = 13).</div></div><div><h3>Conclusions</h3><div>ESCAT tiers I-III alterations were reported in 79 % YA with MBC which supports the role of molecular profiling in YA. The differences detected in the genomic profiles of YA with BC and older patients may allude to potential different underlying disease biology.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"85 ","pages":"Article 104690"},"PeriodicalIF":7.9,"publicationDate":"2026-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145921137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Concomitant radiation therapy and trastuzumab deruxtecan in metastatic breast cancer: feasibility, safety, and outcomes from a real-life multicentre international cohort","authors":"Luca Visani ,&nbsp;Ivica Ratosa ,&nbsp;Rupert Bartsch ,&nbsp;Barbro Linderholm ,&nbsp;Gaia Griguolo ,&nbsp;Calogero Saieva ,&nbsp;Carlotta Becherini ,&nbsp;Marianna Valzano ,&nbsp;Viola Salvestrini ,&nbsp;Angelika M. Starzer ,&nbsp;Peter Kus ,&nbsp;Niccolò Bertini ,&nbsp;Andrea Rampini ,&nbsp;Chiara Mattioli ,&nbsp;Domen Ribnikar ,&nbsp;Jacopo Nori Cucchiari ,&nbsp;Lorenzo Orzalesi ,&nbsp;Simonetta Bianchi ,&nbsp;Matteo Lambertini ,&nbsp;Valentina Guarneri ,&nbsp;Icro Meattini","doi":"10.1016/j.breast.2026.104691","DOIUrl":"10.1016/j.breast.2026.104691","url":null,"abstract":"<div><h3>Background and purpose</h3><div>Radiation therapy (RT) remains a cornerstone of management for metastatic breast cancer (mBC), though systemic therapy drives overall disease control. Administering RT concomitantly with systemic treatment may raise concerns regarding toxicity. This multicentre retrospective study evaluated the safety of trastuzumab deruxtecan (T-DXd), an antibody–drug conjugate, when delivered alongside RT.</div></div><div><h3>Materials and methods</h3><div>Data from six European centres were analysed. Concomitancy was defined as RT administered during T-DXd or within 10 days of a treatment cycle. The primary endpoint was the incidence of grade ≥3 adverse events (AEs). Exploratory endpoints included progression-free survival (PFS) and overall survival (OS).</div></div><div><h3>Results</h3><div>A total of 147 patients were included; 67 received concomitant RT (71 courses) and 80 received T-DXd alone. Median age was 49 years (range 25–85). The central nervous system was the most frequent RT site (54.9 %). Grade ≥3 AEs occurred in 24 patients (16.3 %), with no significant difference between RT and no-RT cohorts (11.9 % vs 20.0 %; p = 0.30). Permanent T-DXd discontinuation due to toxicity occurred in 19 patients (12.9 %), with similar rates in the RT and no-RT groups (11.9 % vs 13.8 %). One case of symptomatic radionecrosis was observed after intracranial RT. Exploratory analyses showed no adverse effect of concomitant RT on PFS or OS.</div></div><div><h3>Conclusion</h3><div>Concomitant administration of T-DXd and RT appears feasible and well tolerated, without increased risk of severe or treatment-limiting toxicity. These real-world findings support the safety of this combination and warrant confirmation in prospective studies.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"85 ","pages":"Article 104691"},"PeriodicalIF":7.9,"publicationDate":"2026-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145910433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The overlooked publication: Forrest (1880) as the earliest report of male mammary Paget's disease","authors":"Wiebren A. Tjalma M.D., Ph.D., FEBS (Hon)","doi":"10.1016/j.breast.2025.104688","DOIUrl":"10.1016/j.breast.2025.104688","url":null,"abstract":"","PeriodicalId":9093,"journal":{"name":"Breast","volume":"85 ","pages":"Article 104688"},"PeriodicalIF":7.9,"publicationDate":"2025-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145910460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Age-stratified toxicity patterns of CDK4/6 inhibitors in older women with breast cancer: Disproportionality analysis from the FAERS database","authors":"Bahadır Köylü ,&nbsp;Buğra Han Esen ,&nbsp;Cevat İlteriş Kıkılı ,&nbsp;Fatih Kemik ,&nbsp;Nazan Demir ,&nbsp;Şeyda Gündüz ,&nbsp;Şahin Laçin ,&nbsp;Deniz Tural ,&nbsp;Didem Tunalı ,&nbsp;Gülistan Bahat ,&nbsp;Fatih Selçukbiricik","doi":"10.1016/j.breast.2025.104687","DOIUrl":"10.1016/j.breast.2025.104687","url":null,"abstract":"<div><h3>Background</h3><div>Despite their benefits, the safety of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors in older patients remains underexplored. We aimed to investigate the toxicities associated with CDK4/6 inhibitors in subgroups of older patients, through analysis of the FAERS database.</div></div><div><h3>Methods</h3><div>In this retrospective pharmacovigilance analysis, we identified 49,223 females with breast cancer (aged 18–100 years), in which a CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib) was recorded as the primary suspect drug. Patients were stratified into four age groups: &lt;65, 65–74, 75–84, and ≥85 years. Disproportionality analysis using the reporting odds ratio method was conducted to detect positive disproportionality signals between individual adverse events and CDK4/6 inhibitors. We performed age-stratified multivariate analyses to detect age-related differences.</div></div><div><h3>Results</h3><div>Acute renal failure and interstitial lung disease associated with abemaciclib were reported more frequently in geriatric age subgroups, while gastrointestinal and hematologic adverse events showed a declining reporting frequency with advancing age. Significant age-related increases in the odds of reporting dementia, hearing and vestibular disorders, lens disorders, arthritis, thrombotic events, and central nervous system hemorrhagic complications were identified in palbociclib-treated patients. Ribociclib showed increased reporting of acute renal failure, chronic kidney disease, cardiac arrhythmias, and ischemic heart disease in geriatric age subgroups, whereas the reporting frequency of liver-related adverse events declined with advancing age.</div></div><div><h3>Conclusions</h3><div>Older adults receiving CDK4/6 inhibitors experience higher rates of renal, pulmonary, cardiac, and neurocognitive toxicities, with abemaciclib linked to renal and pulmonary, palbociclib to neurological and thrombotic/hemorrhagic, and ribociclib to renal and cardiac adverse events.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"85 ","pages":"Article 104687"},"PeriodicalIF":7.9,"publicationDate":"2025-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145910441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}